OTR Therapeutics, a Shanghai-based biotech, closed a $100 million Series A to build a diversified R&D and asset portfolio, with participation from Pfizer Ventures. The company said it will combine in-house discovery with acquired programs—adding preclinical neurological candidates and expanding its research capabilities. Management framed the round as a move to create a China-based research hub with global ambitions, leveraging investor capital to accelerate preclinical programs into IND-enabling work and to broaden therapeutic focus beyond neurological targets. For global pharma and venture investors, the deal underscores continued strategic interest in China-based R&D platforms and in partnerships that can feed both local and international pipelines. Watch for potential deal flow linking Chinese discovery hubs with Western development and commercialization partners.